CoChat
Sign Up
Cited by 643

The DOI matches its Crossref record, with a small difference in title or year; 28 of the 28 references it cites were found in a registry or an index.

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

Ommen, Steve R., Mital, Seema, Burke, Michael A., Day, Sharlene M., Deswal, Anita, Elliott, Perry, Evanovich, Lauren L., Hung, Judy, Joglar, José A., Kantor, Paul, Kimmelstiel, Carey, Kittleson, Michelle, Link, Mark S., Maron, Martin S., Martinez, Matthew W., Miyake, Christina Y., Schaff, Hartzell V., Semsarian, Christopher, Sorajja, Paul·2020·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2020.08.045
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2020.08.045

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Contemporary guidelines recommend assessment for symptoms of sleep-disordered breathing and OSA with referral for evaluation and treatment when present.

    “contemporary guidelines now recommend assessment for symptoms of sleep-disordered breathing and OSA with referral for evaluation and treatment when present.1”

    From GLP-1 Receptor Agonist Use and Long-Term Outcomes in Hypertrophic Cardiomyopathy With Obstructive Sleep Apnea (2026) · cites this paper as [1]

    Section 9.4 (Comorbidities; page unavailable) says sleep-disordered breathing is common in patients with HCM and discusses diagnosis and treatment of obstructive sleep apnea. A reference cross-link in that section also contains the fragment “specialist for evaluation and treatment.” The available passages do not show the specific recommendation to assess symptoms and refer patients when symptoms are present. (LLM, conf=0.78)

    Experimental — accuracy not yet measured

  • Sleep-disordered breathing and obstructive sleep apnea (OSA) are common in hypertrophic cardiomyopathy (HCM).

    “Sleep-disordered breathing and obstructive sleep apnea (OSA) are common in HCM.1”

    From GLP-1 Receptor Agonist Use and Long-Term Outcomes in Hypertrophic Cardiomyopathy With Obstructive Sleep Apnea (2026) · cites this paper as [1]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 673

  1. Anderson, 2014, ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2304, 10.1016/j.jacc.2014.03.016 · DOI
  2. Arnett, 2014, J Am Coll Cardiol, 64, 1851, 10.1016/j.jacc.2014.07.012 · DOI
  3. Levine, 2019, Recent innovations, modifications, and evolution of ACC/AHA clinical practice guidelines: an update for our constituencies: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 73, 1990, 10.1016/j.jacc.2019.02.012 · DOI
  4. Gersh, 2011, J Am Coll Cardiol., 58, e212, 10.1016/j.jacc.2011.06.011 · DOI · Paper page
  5. Elliott, 2014, 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284 · DOI · Paper page
  6. January, 2014, 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, J Am Coll Cardiol, 64, e1, 10.1016/j.jacc.2014.03.022 · DOI · Paper page
  7. January, 2019, J Am Coll Cardiol, 74, 104, 10.1016/j.jacc.2019.01.011 · DOI
  8. Yancy, 2016, J Am Coll Cardiol, 68, 1476, 10.1016/j.jacc.2016.05.011 · DOI
  9. Arnett, 2019, 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 74, e177, 10.1016/j.jacc.2019.03.010 · DOI · Paper page
  10. Jensen, 2014, 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society, J Am Coll Cardiol, 63, 2985, 10.1016/j.jacc.2013.11.004 · DOI · Paper page
  11. Al-Khatib, 2018, J Am Coll Cardiol, 72, e91, 10.1016/j.jacc.2017.10.054 · DOI
  12. Smith, 2011, AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation, J Am Coll Cardiol, 58, 2432, 10.1016/j.jacc.2011.10.824 · DOI
  13. Greenland, 2010, 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 56, e50, 10.1016/j.jacc.2010.09.001 · DOI
  14. Jones, 2004, Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure and evidence from new hypertension trials, Hypertension, 43, 1, 10.1161/01.HYP.0000110061.06674.ca · DOI
  15. Nishimura, 2019, J Am Coll Cardiol, 73, 2609, 10.1016/j.jacc.2018.10.007 · DOI
  16. 2010, Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines, American College of Cardiology and American Heart Association
  17. Burns, 2018, Disparities in the diagnosis of hypertrophic obstructive cardiomyopathy: a narrative review of current literature, Cardiol Res Pract, 2018, 3750879, 10.1155/2018/3750879 · DOI
  18. Semsarian, 2015, New perspectives on the prevalence of hypertrophic cardiomyopathy, J Am Coll Cardiol, 65, 1249, 10.1016/j.jacc.2015.01.019 · DOI
  19. Maron, 2016, Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States, Am J Cardiol, 117, 1651, 10.1016/j.amjcard.2016.02.044 · DOI
  20. Maron, 2018, Clinical course and management of hypertrophic cardiomyopathy, N Engl J Med, 379, 655, 10.1056/NEJMra1710575 · DOI · Paper page
  21. Maron, 2016, How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice, JAMA Cardiol, 1, 98, 10.1001/jamacardio.2015.0354 · DOI · Paper page
  22. Maron, 2015, Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies, J Am Coll Cardiol, 65, 1915, 10.1016/j.jacc.2015.02.061 · DOI · Paper page
  23. Keegan, 2000, Dynamic left ventricular outflow tract obstruction in acute coronary syndromes, Mayo Clin Proc, 75, 216, 10.1016/S0025-6196(11)64198-0 · DOI
  24. Sherrid, 2020, Distinctive hypertrophic cardiomyopathy anatomy and obstructive physiology in patients admitted with Takotsubo syndrome, Am J Cardiol, 125, 1700, 10.1016/j.amjcard.2020.02.013 · DOI
  25. Geske, 2018, Hypertrophic cardiomyopathy: clinical update, J Am Coll Cardiol HF, 6, 364
  26. Marian, 2017, Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy, Circ Res, 121, 749, 10.1161/CIRCRESAHA.117.311059 · DOI · Paper page
  27. Maron, 2014, Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine, J Am Coll Cardiol, 64, 83, 10.1016/j.jacc.2014.05.003 · DOI · Paper page
  28. Maron, 2018, Clinical course and management of hypertrophic cardiomyopathy, N Engl J Med, 379, 655, 10.1056/NEJMra1710575 · DOI · Paper page
  29. Burke, 2016, Clinical and mechanistic insights into the genetics of cardiomyopathy, J Am Coll Cardiol, 68, 2871, 10.1016/j.jacc.2016.08.079 · DOI
  30. Ingles, 2017, Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications, Circ Cardiovasc Genet, 10, 10.1161/CIRCGENETICS.116.001620 · DOI
  31. Ho, 2018, Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRE), Circulation, 138, 1387, 10.1161/CIRCULATIONAHA.117.033200 · DOI · Paper page
  32. Ho, 2018, Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRE), Circulation, 138, 1387, 10.1161/CIRCULATIONAHA.117.033200 · DOI · Paper page
  33. Maron, 2016, How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice, JAMA Cardiol, 1, 98, 10.1001/jamacardio.2015.0354 · DOI · Paper page
  34. Maron, 2018, Clinical course and management of hypertrophic cardiomyopathy, N Engl J Med, 379, 655, 10.1056/NEJMra1710575 · DOI · Paper page
  35. Maron, 2006, Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction, Circulation, 114, 2232, 10.1161/CIRCULATIONAHA.106.644682 · DOI
  36. Kim, 2010, In vivo measurement of mitral leaflet surface area and subvalvular geometry in patients with asymmetrical septal hypertrophy: insights into the mechanism of outflow tract obstruction, Circulation, 122, 1298, 10.1161/CIRCULATIONAHA.109.935551 · DOI
  37. Sherrid, 2000, Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 36, 1344, 10.1016/S0735-1097(00)00830-5 · DOI
  38. Patel, 2015, Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography, Circ Cardiovasc Imaging, 8, 10.1161/CIRCIMAGING.115.003132 · DOI
  39. Numata, 2015, Excess anterior mitral leaflet in a patient with hypertrophic obstructive cardiomyopathy and systolic anterior motion, Circulation, 131, 1605, 10.1161/CIRCULATIONAHA.114.013830 · DOI
  40. Maron, 2003, Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy, N Engl J Med, 348, 295, 10.1056/NEJMoa021332 · DOI · Paper page
  41. Sorajja, 2009, Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study, J Am Coll Cardiol, 54, 234, 10.1016/j.jacc.2009.01.079 · DOI
  42. Geske, 2011, Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy, J Am Coll Cardiol Intv, 4, 704, 10.1016/j.jcin.2011.02.014 · DOI
  43. Adams, 2015, Postprandial hemodynamics in hypertrophic cardiomyopathy, Echocardiography, 32, 1614, 10.1111/echo.12951 · DOI
  44. Jain, 2018, Marked respiratory-related fluctuations in left ventricular outflow tract gradients in hypertrophic obstructive cardiomyopathy: An observational study, Eur Heart J Cardiovasc Imaging., 19, 1126, 10.1093/ehjci/jex215 · DOI
  45. Ayoub, 2017, Comparison of Valsalva maneuver, amyl nitrite, and exercise echocardiography to demonstrate latent left ventricular outflow obstruction in hypertrophic cardiomyopathy, Am J Cardiol, 120, 2265, 10.1016/j.amjcard.2017.08.047 · DOI
  46. Nistri, 2010, Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy, Am J Cardiol, 106, 1301, 10.1016/j.amjcard.2010.06.057 · DOI
  47. Reant, 2018, Upright treadmill vs. semi-supine bicycle exercise echocardiography to provoke obstruction in symptomatic hypertrophic cardiomyopathy: a pilot study, Eur Heart J Cardiovasc Imaging, 19, 31, 10.1093/ehjci/jew313 · DOI
  48. Joshi, 2011, Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity, J Am Soc Echocardiogr, 24, 75, 10.1016/j.echo.2010.10.006 · DOI
  49. Feiner, 2013, Post-prandial upright exercise echocardiography in hypertrophic cardiomyopathy, J Am Coll Cardiol, 61, 2487, 10.1016/j.jacc.2013.02.079 · DOI
  50. Pellikka, 1992, Dynamic intraventricular obstruction during dobutamine stress echocardiography. A new observation, Circulation, 86, 1429, 10.1161/01.CIR.86.5.1429 · DOI
  51. Elesber, 2008, Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy, Am J Cardiol, 101, 516, 10.1016/j.amjcard.2007.09.111 · DOI
  52. Paulus, 1983, Comparison of the effects of nitroprusside and nifedipine on diastolic properties in patients with hypertrophic cardiomyopathy: altered left ventricular loading or improved muscle inactivation?, J Am Coll Cardiol, 2, 879, 10.1016/S0735-1097(83)80235-6 · DOI
  53. Soullier, 2012, Exercise response in hypertrophic cardiomyopathy: blunted left ventricular deformational and twisting reserve with altered systolic-diastolic coupling, Circ Cardiovasc Imaging, 5, 324, 10.1161/CIRCIMAGING.111.968859 · DOI
  54. Villemain, 2019, Myocardial stiffness evaluation using noninvasive shear wave imaging in healthy and hypertrophic cardiomyopathic adults, J Am Coll Cardiol Img, 12, 1135, 10.1016/j.jcmg.2018.02.002 · DOI
  55. Dass, 2015, Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction, Eur Heart J, 36, 1547, 10.1093/eurheartj/ehv120 · DOI
  56. Desai, 2014, Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes, J Am Coll Cardiol Img, 7, 26, 10.1016/j.jcmg.2013.08.010 · DOI
  57. Chan, 2014, Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy, Circulation, 130, 484, 10.1161/CIRCULATIONAHA.113.007094 · DOI · Paper page
  58. Olivotto, 2010, Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy, Am J Cardiol, 106, 261, 10.1016/j.amjcard.2010.03.020 · DOI
  59. Sivalokanathan, 2019, Hypertrophic cardiomyopathy patients with paroxysmal atrial fibrillation have a high burden of left atrial fibrosis by cardiac magnetic resonance imaging, J Am Coll Cardiol EP, 5, 364
  60. Hang, 2019, Accuracy of jet direction on Doppler echocardiography in identifying the etiology of mitral regurgitation in obstructive hypertrophic cardiomyopathy, J Am Soc Echocardiogr, 32, 333, 10.1016/j.echo.2018.10.011 · DOI
  61. Maron, 2011, Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy, Circulation, 124, 40, 10.1161/CIRCULATIONAHA.110.985812 · DOI
  62. Groarke, 2018, Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers, Eur Heart J Cardiovasc Imaging, 19, 1109, 10.1093/ehjci/jey095 · DOI
  63. Sherrid, 2016, The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context, J Am Coll Cardiol, 67, 1846, 10.1016/j.jacc.2016.01.071 · DOI
  64. Hodges, 2019, Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center, J Thorac Cardiovasc Surg, 157, 2289, 10.1016/j.jtcvs.2018.11.148 · DOI
  65. Hong, 2016, Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures, J Am Coll Cardiol, 68, 1497, 10.1016/j.jacc.2016.07.735 · DOI · Paper page
  66. Cannon, 1985, Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures, Circulation, 71, 234, 10.1161/01.CIR.71.2.234 · DOI
  67. Maron, 1986, Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy, J Am Coll Cardiol, 8, 545, 10.1016/S0735-1097(86)80181-4 · DOI
  68. Karamitsos, 2013, Blunted myocardial oxygenation response during vasodilator stress in patients with hypertrophic cardiomyopathy, J Am Coll Cardiol, 61, 1169, 10.1016/j.jacc.2012.12.024 · DOI
  69. Raphael, 2016, Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy: insights from wave intensity analysis and magnetic resonance, J Am Coll Cardiol, 68, 1651, 10.1016/j.jacc.2016.07.751 · DOI
  70. Sorajja, 2003, Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease, Circulation, 108, 2342, 10.1161/01.CIR.0000097110.55312.BF · DOI
  71. Bravo, 2013, Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy, Circ Cardiovasc Imaging, 6, 210, 10.1161/CIRCIMAGING.112.000110 · DOI
  72. Rowin, 2017, Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management, J Am Coll Cardiol, 69, 761, 10.1016/j.jacc.2016.11.063 · DOI
  73. Binder, 2011, Apical hypertrophic cardiomyopathy: prevalence and correlates of apical outpouching, J Am Soc Echocardiogr, 24, 775, 10.1016/j.echo.2011.03.002 · DOI
  74. Hostiuc, 2017, Cardiovascular consequences of myocardial bridging: a meta-analysis and meta-regression, Sci Rep, 7, 14644, 10.1038/s41598-017-13958-0 · DOI
  75. Sharzehee, 2019, Hemodynamic effects of myocardial bridging in patients with hypertrophic cardiomyopathy, Am J Physiol Heart Circ Physiol, 317, 10.1152/ajpheart.00466.2019 · DOI
  76. Tian, 2014, Myocardial bridging as a common phenotype of hypertrophic cardiomyopathy has no effect on prognosis, Am J Med Sci, 347, 429, 10.1097/MAJ.0000000000000194 · DOI
  77. Yetman, 1998, Myocardial bridging in children with hypertrophic cardiomyopathy--a risk factor for sudden death, N Engl J Med, 339, 1201, 10.1056/NEJM199810223391704 · DOI
  78. Zhai, 2018, Clinical outcomes of myocardial bridging versus no myocardial bridging in patients with apical hypertrophic cardiomyopathy, Cardiology, 139, 161, 10.1159/000486276 · DOI
  79. Patel, 2014, Heart rate recovery in patients with hypertrophic cardiomyopathy, Am J Cardiol, 113, 1011, 10.1016/j.amjcard.2013.11.062 · DOI
  80. Frenneaux, 1990, Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy, Circulation, 82, 1995, 10.1161/01.CIR.82.6.1995 · DOI
  81. Sadoul, 1997, Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy, Circulation, 96, 2987, 10.1161/01.CIR.96.9.2987 · DOI
  82. Olivotto, 1999, Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy, J Am Coll Cardiol, 33, 2044, 10.1016/S0735-1097(99)00094-7 · DOI
  83. Greenfield, 1988, Patients' participation in medical care: effects on blood sugar control and quality of life in diabetes, J Gen Intern Med, 3, 448, 10.1007/BF02595921 · DOI
  84. Greenfield, 1985, Expanding patient involvement in care. Effects on patient outcomes, Ann Intern Med, 102, 520, 10.7326/0003-4819-102-4-520 · DOI
  85. Kaplan, 1989, Assessing the effects of physician-patient interactions on the outcomes of chronic disease, Med Care, 27, S110, 10.1097/00005650-198903001-00010 · DOI · Paper page
  86. Guadagnoli, 1998, Patient participation in decision-making, Soc Sci Med, 47, 329, 10.1016/S0277-9536(98)00059-8 · DOI
  87. Kim, 2016, Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003-2011, JAMA Cardiol, 1, 324, 10.1001/jamacardio.2016.0252 · DOI
  88. Panaich, 2014, Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample [1998-2010]), Am J Cardiol, 114, 1390, 10.1016/j.amjcard.2014.07.075 · DOI
  89. Sorajja, 2012, Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy, Circulation, 126, 2374, 10.1161/CIRCULATIONAHA.111.076257 · DOI
  90. Maron, 2017, Shared decision-making in HCM, Nat Rev Cardiol, 14, 125, 10.1038/nrcardio.2017.6 · DOI
  91. Chambers, 2017, Standards defining a 'Heart Valve Centre': ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint, Eur Heart J, 38, 2177, 10.1093/eurheartj/ehx370 · DOI
  92. Semsarian, 2015, New perspectives on the prevalence of hypertrophic cardiomyopathy, J Am Coll Cardiol, 65, 1249, 10.1016/j.jacc.2015.01.019 · DOI
  93. Maron, 2014, Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine, J Am Coll Cardiol, 64, 83, 10.1016/j.jacc.2014.05.003 · DOI · Paper page
  94. Ommen, 2005, Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 46, 470, 10.1016/j.jacc.2005.02.090 · DOI
  95. Desai, 2013, Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction, Circulation, 128, 209, 10.1161/CIRCULATIONAHA.112.000849 · DOI · Paper page
  96. Lim, 2009, Successful catheter ablation of hemodynamically unstable monomorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and apical aneurysm, J Cardiovasc Electrophysiol, 20, 445, 10.1111/j.1540-8167.2008.01366.x · DOI
  97. Dukkipati, 2011, Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy, Circ Arrhythm Electrophysiol, 4, 185, 10.1161/CIRCEP.110.957290 · DOI
  98. Rowin, 2018, Impact of advanced therapies for improving survival to heart transplant in patients with hypertrophic cardiomyopathy, Am J Cardiol, 121, 986, 10.1016/j.amjcard.2017.12.044 · DOI
  99. Pasqualucci, 2015, Clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy, Circ Heart Fail, 8, 1014, 10.1161/CIRCHEARTFAILURE.114.001843 · DOI · Paper page
  100. Nishimura, 2019, J Am Coll Cardiol, 73, 2609, 10.1016/j.jacc.2018.10.007 · DOI
  101. Polanco, 2020, Impact of septal myectomy volume on mitral-valve replacement rate in hypertrophic cardiomyopathy patients, Cardiology, 145, 161, 10.1159/000504215 · DOI
  102. Holst, 2019, Septal myectomy in hypertrophic cardiomyopathy: national outcomes of concomitant mitral surgery, Mayo Clin Proc, 94, 66, 10.1016/j.mayocp.2018.07.022 · DOI
  103. Maron, 2012, Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives, J Am Coll Cardiol, 60, 705, 10.1016/j.jacc.2012.02.068 · DOI
  104. Ingles, 2011, The emerging role of the cardiac genetic counselor, Heart Rhythm, 8, 1958, 10.1016/j.hrthm.2011.07.017 · DOI
  105. Ahmad, 2019, Establishment of specialized clinical cardiovascular genetics programs: recognizing the need and meeting standards: a scientific statement from the American Heart Association, Circ Genom Precis Med, 12, 10.1161/HCG.0000000000000054 · DOI
  106. van Velzen, 2018, Outcomes of contemporary family screening in hypertrophic cardiomyopathy, Circ Genom Precis Med, 11, 10.1161/CIRCGEN.117.001896 · DOI · Paper page
  107. Ranthe, 2015, Risk of cardiomyopathy in younger persons with a family history of death from cardiomyopathy: a nationwide family study in a cohort of 3.9 million persons, Circulation, 132, 1013, 10.1161/CIRCULATIONAHA.114.013478 · DOI
  108. Lafreniere-Roula, 2019, Family screening for hypertrophic cardiomyopathy: Is it time to change practice guidelines?, Eur Heart J, 40, 3672, 10.1093/eurheartj/ehz396 · DOI
  109. Adabag, 2006, Determinants for clinical diagnosis of hypertrophic cardiomyopathy, Am J Cardiol, 98, 1507, 10.1016/j.amjcard.2006.07.029 · DOI
  110. Afonso, 2008, Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technologies, J Am Coll Cardiol Img, 1, 787, 10.1016/j.jcmg.2008.09.002 · DOI
  111. Klues, 1995, Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients, J Am Coll Cardiol, 26, 1699, 10.1016/0735-1097(95)00390-8 · DOI
  112. Wigle, 1985, Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review, Prog Cardiovasc Dis, 28, 1, 10.1016/0033-0620(85)90024-6 · DOI
  113. Shapiro, 1983, Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study, J Am Coll Cardiol, 2, 437, 10.1016/S0735-1097(83)80269-1 · DOI
  114. Nagueh, 2011, American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy, J Am Soc Echocardiogr, 24, 473, 10.1016/j.echo.2011.03.006 · DOI
  115. Douglas, 2011, J Am Coll Cardiol, 57, 1126, 10.1016/j.jacc.2010.11.002 · DOI
  116. Melacini, 2010, Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy, Eur Heart J, 31, 2111, 10.1093/eurheartj/ehq136 · DOI
  117. Thaman, 2005, Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy, Heart, 91, 920, 10.1136/hrt.2003.031161 · DOI
  118. Harris, 2006, Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy, Circulation, 114, 216, 10.1161/CIRCULATIONAHA.105.583500 · DOI
  119. Olivotto, 2012, Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging, Circ Heart Fail, 5, 535, 10.1161/CIRCHEARTFAILURE.112.967026 · DOI
  120. Todiere, 2012, Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy, J Am Coll Cardiol, 60, 922, 10.1016/j.jacc.2012.03.076 · DOI
  121. Norrish, 2019, A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy, Europace, 21, 1559, 10.1093/europace/euz118 · DOI
  122. Balaji, 2019, Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: an international multicenter study, Heart Rhythm, 16, 1462, 10.1016/j.hrthm.2019.04.040 · DOI
  123. Maron, 2003, Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy, N Engl J Med, 348, 295, 10.1056/NEJMoa021332 · DOI · Paper page
  124. Woo, 2005, Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy, Circulation, 111, 2033, 10.1161/01.CIR.0000162460.36735.71 · DOI
  125. Geske, 2007, Evaluation of left ventricular filling pressures by doppler echocardiography in patients with hypertrophic cardiomyopathy, Circulation, 116, 2702, 10.1161/CIRCULATIONAHA.107.698985 · DOI
  126. Rakowski, 2007, Quantifying diastolic function in hypertrophic cardiomyopathy: the ongoing search for the holy grail, Circulation, 116, 2662, 10.1161/CIRCULATIONAHA.107.742395 · DOI
  127. Kumar, 2018, Standardized goal-directed Valsalva maneuver for assessment of inducible left ventricular outflow tract obstruction in hypertrophic cardiomyopathy, J Am Soc Echocardiogr, 31, 791, 10.1016/j.echo.2018.01.022 · DOI
  128. Marwick, 1995, Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy, Am J Cardiol, 75, 805, 10.1016/S0002-9149(99)80416-0 · DOI
  129. Joshi, 2011, Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity, J Am Soc Echocardiogr, 24, 75, 10.1016/j.echo.2010.10.006 · DOI
  130. Maron, 2006, Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction, Circulation, 114, 2232, 10.1161/CIRCULATIONAHA.106.644682 · DOI
  131. Ayoub, 2017, Comparison of Valsalva maneuver, amyl nitrite, and exercise echocardiography to demonstrate latent left ventricular outflow obstruction in hypertrophic cardiomyopathy, Am J Cardiol, 120, 2265, 10.1016/j.amjcard.2017.08.047 · DOI
  132. Jensen, 2010, Comparison of Valsalva manoeuvre and exercise in echocardiographic evaluation of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy, Eur J Echocardiogr, 11, 763, 10.1093/ejechocard/jeq063 · DOI
  133. Reant, 2018, Upright treadmill vs. semi-supine bicycle exercise echocardiography to provoke obstruction in symptomatic hypertrophic cardiomyopathy: a pilot study, Eur Heart J Cardiovasc Imaging, 19, 31, 10.1093/ehjci/jew313 · DOI
  134. Shah, 2008, Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy, Heart, 94, 1288, 10.1136/hrt.2007.126003 · DOI
  135. Grigg, 1992, Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making, J Am Coll Cardiol, 20, 42, 10.1016/0735-1097(92)90135-A · DOI
  136. Marwick, 1992, Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy, J Am Coll Cardiol, 20, 1066, 10.1016/0735-1097(92)90359-U · DOI
  137. Nampiaparampil, 2018, Intraoperative two- and three-dimensional transesophageal echocardiography in combined myectomy-mitral operations for hypertrophic cardiomyopathy., J Am Soc Echocardiogr, 31, 275, 10.1016/j.echo.2017.11.016 · DOI
  138. Ommen, 2002, Impact of intraoperative transesophageal echocardiography in the surgical management of hypertrophic cardiomyopathy, Am J Cardiol, 90, 1022, 10.1016/S0002-9149(02)02694-2 · DOI
  139. Faber, 1999, Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area, Catheter Cardiovasc Interv, 47, 462
  140. Faber, 2000, Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring, J Am Soc Echocardiogr, 13, 1074, 10.1067/mje.2000.108250 · DOI
  141. Nagueh, 2015, Role of imaging in the evaluation of patients at risk for sudden cardiac death: genotype-phenotype intersection, J Am Coll Cardiol Img, 8, 828, 10.1016/j.jcmg.2015.04.006 · DOI
  142. Faber, 2004, Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience, Eur J Echocardiogr, 5, 347, 10.1016/j.euje.2004.01.001 · DOI
  143. Kuhn, 1999, Eur Heart J, 20, 1808, 10.1053/euhj.1999.1692 · DOI
  144. Sorajja, 2008, Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy, Circulation, 118, 131, 10.1161/CIRCULATIONAHA.107.738740 · DOI
  145. Faber, 1998, Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography, Circulation, 98, 2415, 10.1161/01.CIR.98.22.2415 · DOI
  146. Qin, 2001, Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery, J Am Coll Cardiol, 38, 1994
  147. Ommen, 2005, Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 46, 470, 10.1016/j.jacc.2005.02.090 · DOI
  148. Jensen Morten, 2013, Penetrance of hypertrophic cardiomyopathy in children and adolescents, Circulation, 127, 48, 10.1161/CIRCULATIONAHA.111.090514 · DOI
  149. Lafreniere-Roula, 2019, Family screening for hypertrophic cardiomyopathy: Is it time to change practice guidelines?, Eur Heart J, 40, 3672, 10.1093/eurheartj/ehz396 · DOI
  150. Maurizi, 2019, Clinical course and significance of hypertrophic cardiomyopathy without left ventricular hypertrophy, Circulation, 139, 830, 10.1161/CIRCULATIONAHA.118.037264 · DOI
  151. Norrish, 2019, Yield of clinical screening for hypertrophic cardiomyopathy in child first-degree relatives, Circulation, 140, 184, 10.1161/CIRCULATIONAHA.118.038846 · DOI
  152. Vermeer, 2017, Penetrance of hypertrophic cardiomyopathy in children who are mutation positive, J Pediatr., 188, 91, 10.1016/j.jpeds.2017.03.033 · DOI
  153. Thanigaraj, 2000, Apical hypertrophic cardiomyopathy: echocardiographic diagnosis with the use of intravenous contrast image enhancement, J Am Soc Echocardiogr, 13, 146, 10.1016/S0894-7317(00)90026-9 · DOI
  154. Porter, 2018, Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography guidelines update, J Am Soc Echocardiogr, 31, 241, 10.1016/j.echo.2017.11.013 · DOI
  155. Feiner, 2013, Post-prandial upright exercise echocardiography in hypertrophic cardiomyopathy, J Am Coll Cardiol, 61, 2487, 10.1016/j.jacc.2013.02.079 · DOI
  156. Faber, 2007, Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances, Int J Cardiol, 119, 163, 10.1016/j.ijcard.2006.07.179 · DOI
  157. Liebregts, 2015, A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy, J Am Coll Cardiol HF, 3, 896
  158. Lafreniere-Roula, 2019, Family screening for hypertrophic cardiomyopathy: Is it time to change practice guidelines?, Eur Heart J, 40, 3672, 10.1093/eurheartj/ehz396 · DOI
  159. Charron, 2010, Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, Eur Heart J, 31, 2715, 10.1093/eurheartj/ehq271 · DOI
  160. Vigneault, 2019, Left ventricular strain is abnormal in preclinical and overt hypertrophic cardiomyopathy: cardiac MR feature tracking, Radiology, 290, 640, 10.1148/radiol.2018180339 · DOI
  161. Nagueh, 2003, Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease, Circulation, 108, 395, 10.1161/01.CIR.0000084500.72232.8D · DOI
  162. Ho, 2002, Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy, Circulation, 105, 2992, 10.1161/01.CIR.0000019070.70491.6D · DOI
  163. Hershberger, 2009, Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy, Circ Heart Fail, 2, 253, 10.1161/CIRCHEARTFAILURE.108.817346 · DOI
  164. Jensen, 2013, Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing, Circulation, 127, 48, 10.1161/CIRCULATIONAHA.111.090514 · DOI
  165. Porter, 2018, Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography Guidelines Update, J Am Soc Echocardiogr, 31, 241, 10.1016/j.echo.2017.11.013 · DOI
  166. Ackerman, 2011, HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies, Heart Rhythm, 8, 1308, 10.1016/j.hrthm.2011.05.020 · DOI
  167. Maron, 2009, Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance, J Am Coll Cardiol, 54, 220, 10.1016/j.jacc.2009.05.006 · DOI
  168. Rickers, 2005, Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy, Circulation, 112, 855, 10.1161/CIRCULATIONAHA.104.507723 · DOI
  169. Moon, 2004, Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography, Heart, 90, 645, 10.1136/hrt.2003.014969 · DOI
  170. Hindieh, 2017, Discrepant measurements of maximal left ventricular wall thickness between cardiac magnetic resonance imaging and echocardiography in patients with hypertrophic cardiomyopathy, Circ Cardiovasc Imaging, 10, e006309, 10.1161/CIRCIMAGING.117.006309 · DOI
  171. Corona-Villalobos, 2016, Left ventricular wall thickness in patients with hypertrophic cardiomyopathy: a comparison between cardiac magnetic resonance imaging and echocardiography, Int J Cardiovasc Imaging, 32, 945, 10.1007/s10554-016-0858-4 · DOI
  172. Bois, 2017, Comparison of maximal wall thickness in hypertrophic cardiomyopathy differs between magnetic resonance imaging and transthoracic echocardiography, Am J Cardiol, 119, 643, 10.1016/j.amjcard.2016.11.010 · DOI
  173. Maron, 2017, How to image hypertrophic cardiomyopathy, Circ Cardiovasc Imaging, 10, e0053272, 10.1161/CIRCIMAGING.116.005372 · DOI · Paper page
  174. Rowin, 2017, Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management, J Am Coll Cardiol, 69, 761, 10.1016/j.jacc.2016.11.063 · DOI
  175. Kebed, 2014, Evaluation of apical pouches in hypertrophic cardiomyopathy using cardiac MRI, Int J Cardiovasc Imaging, 30, 591, 10.1007/s10554-013-0355-y · DOI
  176. Maron, 2010, Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance, Am J Cardiol, 105, 1842, 10.1016/j.amjcard.2010.01.367 · DOI
  177. Weng, 2016, Prognostic value of LGE-CMR in HCM: a meta-analysis, J Am Coll Cardiol Img, 9, 1392, 10.1016/j.jcmg.2016.02.031 · DOI
  178. Chan, 2014, Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy, Circulation, 130, 484, 10.1161/CIRCULATIONAHA.113.007094 · DOI · Paper page
  179. Mentias, 2018, Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function, J Am Coll Cardiol, 72, 857, 10.1016/j.jacc.2018.05.060 · DOI
  180. Ismail, 2014, Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy, Heart, 100, 1851, 10.1136/heartjnl-2013-305471 · DOI
  181. Harris, 2006, Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy, Circulation, 114, 216, 10.1161/CIRCULATIONAHA.105.583500 · DOI
  182. Patel, 2015, Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography, Circ Cardiovasc Imaging, 8, 10.1161/CIRCIMAGING.115.003132 · DOI
  183. Rowin, 2018, Clinical spectrum and management implications of left ventricular outflow obstruction with mild ventricular septal thickness in hypertrophic cardiomyopathy, Am J Cardiol, 122, 1409, 10.1016/j.amjcard.2018.06.055 · DOI
  184. Sherrid, 2016, The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context, J Am Coll Cardiol, 67, 1846, 10.1016/j.jacc.2016.01.071 · DOI
  185. Kwon, 2008, Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy, Heart, 94, 1295, 10.1136/hrt.2007.118018 · DOI
  186. Rowin, 2013, Papillary muscle insertion directly into the anterior mitral leaflet in hypertrophic cardiomyopathy, its identification and cause of outflow obstruction by cardiac magnetic resonance imaging, and its surgical management, Am J Cardiol, 111, 1677, 10.1016/j.amjcard.2013.01.340 · DOI
  187. Rubinshtein, 2010, Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy, Circ Heart Fail, 3, 51, 10.1161/CIRCHEARTFAILURE.109.854026 · DOI
  188. Todiere, 2012, Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy, J Am Coll Cardiol, 60, 922, 10.1016/j.jacc.2012.03.076 · DOI
  189. Douglas, 2011, J Am Coll Cardiol, 57, 1126, 10.1016/j.jacc.2010.11.002 · DOI
  190. Nagueh, 2011, American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy, J Am Soc Echocardiogr, 24, 473, 10.1016/j.echo.2011.03.006 · DOI
  191. Langer, 2014, Hypertrophic cardiomyopathy in cardiac CT: a validation study on the detection of intramyocardial fibrosis in consecutive patients, Int J Cardiovasc Imaging, 30, 659, 10.1007/s10554-013-0358-8 · DOI
  192. Zhao, 2014, Quantification of myocardial delayed enhancement and wall thickness in hypertrophic cardiomyopathy: multidetector computed tomography versus magnetic resonance imaging, Eur J Radiol, 83, 1778, 10.1016/j.ejrad.2014.05.035 · DOI
  193. Maron, 2001, The electrocardiogram as a diagnostic tool for hypertrophic cardiomyopathy: revisited, Ann Noninvasive Electrocardiol, 6, 277, 10.1111/j.1542-474X.2001.tb00118.x · DOI
  194. Panza, 1989, Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood, Am J Cardiol, 63, 1258, 10.1016/0002-9149(89)90187-2 · DOI
  195. Zorzi, 2018, Accuracy of the ECG for differential diagnosis between hypertrophic cardiomyopathy and athlete's heart: comparison between the European Society of Cardiology (2010) and International (2017) criteria, Br J Sports Med, 52, 667, 10.1136/bjsports-2016-097438 · DOI
  196. Maron, 1981, Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study, Am J Cardiol, 48, 252, 10.1016/0002-9149(81)90604-4 · DOI
  197. Monserrat, 2003, Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients, J Am Coll Cardiol, 42, 873, 10.1016/S0735-1097(03)00827-1 · DOI · Paper page
  198. Wilke, 2016, High incidence of de novo and subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac rhythm management device, J Cardiovasc Electrophysiol, 27, 779, 10.1111/jce.12982 · DOI
  199. van Velzen, 2017, Incidence of device-detected atrial fibrillation and long-term outcomes in patients with hypertrophic cardiomyopathy, Am J Cardiol, 119, 100, 10.1016/j.amjcard.2016.08.092 · DOI
  200. Rowin, 2017, Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy, Circulation, 136, 2420, 10.1161/CIRCULATIONAHA.117.029267 · DOI · Paper page

200 of 673 shown

Cited by

Sorted by citations

Metadata

Authors
Ommen, S. R., Mital, S., Burke, M. A., Day, S. M., Deswal, A., Elliott, P., Evanovich, L. L., Hung, J., Joglar, J. A., Kantor, P., Kimmelstiel, C., Kittleson, M., Link, M. S., Maron, M. S., Martinez, M. W., Miyake, C. Y., Schaff, H. V., Semsarian, C., & Sorajja, P.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2020-12
Volume
76
Issue
25
Pages
e159-e240
ISSN
0735-1097
DOI
10.1016/j.jacc.2020.08.045
Cited by
643
References
28
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review